Over the 2 days of the Summit, we had presentations from the following invited speakers:
Professor Alan Silman
Professor of Musculoskeletal Health, University of Oxford and former Medical Director of Arthritis Research UK.
Alan Silman is an epidemiologist and a rheumatologist. He was Director of the UK’s Arthritis Research Epidemiology Unit in Manchester from 1988-2006. He then became ARUK’s first Medical Director, a post he held from 2007 until the end of 2014. Currently he is Professor of Musculoskeletal Health at Oxford University. He has published over 500 articles in the broad field of arthritis and musculoskeletal diseases and is one of the editors of the leading international postgraduate textbook, Rheumatology (6th Edn Elsevier 2014). His research interests span pharmacoepidemiology, genetics and outcome research. He has worked in several disease areas including RA, osteoporosis, musculoskeletal pain disorders, scleroderma and Behcets disease. Amongst recent international activities he lead the joint EULAR/ACR taskforce to deliver the current criteria for RA.
Professor John Zalcberg (OAM)
Founding member of the Australasian Gastrointestinal Trials Group (AGITG) and Chair, Australian Clinical Trials Alliance (ACTA) .
Professor John Zalcberg was the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne, Australia for 17 years prior to recently taking up the position of Head, Cancer Research Program in the School of Public Health and Preventative Medicine at Monash University.
After earning a Bachelor of Medicine and Bachelor of Surgery from the University of Melbourne and a PhD in cancer immunology, he served as Director of Medical Oncology at the Heidelberg Repatriation Hospital and as Director of Cancer Services at the Austin and Repatriation Medical Centre.
A founder of the Lorne Cancer Conference and the Australasian Gastrointestinal Trials Group (AGITG), he is immediate past Chair of the Board of AGITG after serving in this role for over 15 years and a past Board Member of Cancer Trials Australia.
He is the current Co-Chair of the Cancer Drugs Alliance, an organization which advocates for improved access to new cancer drugs for patients and also the Interim Chair of the Australian Clinical Trials Alliance. This organization is involved in advocating for embedding clinical research into routine clinical practice in order to improve the quality of health care delivery.
A past Board Member of the NSW Cancer Institute, past President of the Clinical Oncological Society of Australia, and a past Member of the Consultative Council of the Victorian Cancer Agency, he has received a Medal of the Order of Australia Award (OAM), the 2011 Cancer Achievement Award from the Medical Oncology Group of Australia and the 2014 “Tom Reeve Award for Outstanding Contributions to Cancer Care” from the Clinical Oncology Society of Australia.
Professor Zalcberg’s clinical research interests include gastrointestinal cancer and health care outcomes. He has published more than 230 articles in peer-reviewed journals. He was a Principal Investigator for the EORTC advanced GIST trial in Australia and remains active in numerous trials in gastrointestinal malignancies. He continues an active clinical practice in GI cancer.
Ms Ainslie Cahill
Chief Executive Officer, Arthritis Australia
Ainslie Cahill is CEO of Arthritis Australia. This national peak organisation has made significant investments in musculoskeletal research; awareness & education; and health consumer advocacy for more than 30 years.
As well as being a strong and effective health consumer advocate, Ainslie has had a distinguished senior management career in publishing, film & television and vocational education.
She has fulfilled several terms on the Consumers Health Forum Board (2008-2014), including four years as Deputy Chair, and currently serves on The Life Saving Drugs Program Review Reference Group; Clinical Trials Advisory Committee; and Comcare Health Benefits of Work Advisory Group.
Ms Linda Martin
Chief Executive Officer, Arthritis & Osteoporosis Victoria
Ms Linda Martin is the Chief Executive Officer of Arthritis and Osteoporosis Victoria and a Board Director for ANZUP Cancer Trials Group Limited. Linda spearheaded the establishment of the Musculoskeletal Clinical Leadership Group in Victoria and was an inaugural member of this group. She is also an industry representative on the Monash University, School of Public Health and Preventive Medicine Postgraduate Courses Committee.
Linda has had previous roles as a Senior Executive in the Victorian Public Service, working primarily in the community services sector and on major projects. She has also been Managing Director of management consultancy firm Martin, Bonato and Associates and a lecturer in Social Work at the University of Melbourne.
Linda has worked in the health and community service sectors and also in other diverse industries such as banking, insurance and transport safety. She has worked in public, private and not for profit organisations. Her focus has been on governance, strategic and business planning, project management and change management and the development of strategic alliances and networks.
She has a Bachelor of Arts, Bachelor of Social Work and Diploma of Education from Monash University and a Master of Social Work from the University of Melbourne.
Professor Paul Myles
Founding member of the Australian and New Zealand College of Anaesthetists (ANZCA) Trials Group.
Paul Myles is Professor and Director of the Department of Anaesthesia and Perioperative Medicine at the Alfred Hospital in Melbourne, and at Monash University, Australia. He also has an adjunct professorial appointment with the Monash Department of Epidemiology and Preventive Medicine. He has a Master degree in Public Health, a doctorate degree in cardiothoracic anaesthesia.
He is an Australian National Health and Medical Research Council Practitioner Fellow, and is a member of the Research Committee of the Australian and New Zealand College of Anaesthetists.
Paul is an Editor of the British Journal of Anaesthesia, an Editorial Consultant for The Lancet and an editorial board member of Anaesthesia and Intensive Care. He has published more than 200 papers, and been awarded more than 24 NHMRC grants totalling more than $30 million.
The main focus of his research has been on patient quality of recovery, avoidance of postoperative complications, and large multicentre trials in anaesthesia.
Associate Professor Meredith Temple-Smith
Academic lead of APCReN, the Australian Primary Care Research Network.
A/Prof Meredith Temple-Smith is Director of Research Training in the Department of General Practice at the University of Melbourne. She assisted in establishing VicReN, the Victorian general practice based research network, and is Academic Lead for APCReN, the Australian Primary Care Research Network, an umbrella organisation of primary care practice based research networks. A mixed methods researcher, she is currently a Chief Investigator on a substantial suite of projects examining ways to improve and sustain Chlamydia testing in the general practice setting, based on the Australian Chlamydia Control Effectiveness Pilot ACCEPt: a cluster randomised controlled trial of chlamydia testing in general practice. (http://www.thelancet.com/
Professor Alex Collie
Institute for Safety, Compensation and Recovery Research (ISCRR)
Professor Alex Collie is the Chief Executive Officer of ISCRR. He has held research leadership roles in academia, government and industry for the past 15 years. From 2010 to September 2013 he was ISCRR’s Chief Research Officer. Prior to joining ISCRR, he spent four years as Executive Director of the Victorian Neurotrauma Initiative, a state government brain and spinal cord injury research fund and a subsidiary of the Transport Accident Commission (TAC). For 6 years he was a senior scientist with CogState Ltd, an ASX listed cognitive assessment company, including two years establishing its European operations
Alex is also Adjunct Professor (Research) in the Department of Epidemiology and Preventive Medicine at Monash. He has a PhD in psychology and has published over 100 journal articles, reviews and technical reports. He established the Victorian Compensation Research Database (CRD), a unique research platform now used internationally for OH&S, compensation system and return to work research. He currently holds competitive research grants as a Chief Investigator from the National Health and Medical Research Council, the Australian Research Council and the Canadian Institutes of Health Research. With colleagues from New Zealand, he established the Australasian Compensation Health Research Forum, an annual dialogue that engages researchers and practitioners from the Australian and New Zealand injury compensation sector. He is a Churchill Fellow and recipient of a 2010 Australian Leadership Award.
Associate Professor Craig French
Australian and New Zealand Intensive Care Society (ACZICS) Clinical Trials Group
Craig French is the Director of Intensive Care at Western Health in Melbourne and a Clinical Associate Professor at the University of Melbourne. He graduated from the University of Melbourne and is a Fellow of the College of Critical Care Medicine and Australian and New Zealand College of Anaesthetists. His research interests include the conduct of multicentre ICU studies and transfusion medicine in the critically ill. Craig is a Chief Investigator in the EPO TBI and TRANSFUSE studies and the Blood Centre for Research Excellence. He is co-chair of the expert working group overseeing the development of National Patient Blood Management Guidelines and the vice chair of the ANZICS Clinical Trials Group.